Furthermore, EGFL8 exerts an antiproliferative effect on neuroblastoma cells, and higher EGFL8 expression in peripheral neuroblastic tumors correlates with improved clinical outcomes and significantly higher 5-year overall survival rates, potentially owing to its neuritogenic effect [24]. Here, EGFL8 is linked to neuroblastoma.